Overall rank by patents
#24,811
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Microvascular Tissues, Inc.
USPTO PatentsView assignee record - 11 granted patents across 5 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA).
11
Total patents granted
5
CPC technology areas
13.7
Avg claims per patent
+75%
5-year filing velocity
The verdict
Microvascular holds 11 US patents across 5 technology areas, rank #24,811 of 50,000 tracked assignees.
- #24,811
- of 50,000 US assignees by volume
- Top 62%
- by Innovation Score (31.4/100)
- 13.7
- avg claims per patent
- +75%
- filing velocity, last 5 yrs
Portfolio overview
Microvascular Tissues, Inc. has been granted 11 US utility patents between 2015 and 2025, placing Microvascular Tissues, Inc. at rank #24,811 across all assignees tracked by PlainPatent. This portfolio spans 5 distinct Cooperative Patent Classification (CPC) subclasses, averaging 13.7 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a US Corporation, Microvascular Tissues, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Microvascular sits between Mitegen, Llc (11 patents, rank #24,807) and Mindspeed Technologies, Llc. (11 patents, rank #24,815) - the closest US assignees by grant volume. The composite Innovation Score of 31.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 7 grants, compared with 4 in the 2015–2019 window, a +75% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Microvascular Tissues, Inc.'s 13.7 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 5 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Microvascular Tissues, Inc. against peers pursuing similar technology classes.
Who files at Microvascular's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Mitegen
MiTeGen, LLC
11 patents
- Miz
MiZ Company Limited
11 patents
- Michellia
Michellia Inc.
11 patents
- Micro Macro Assets
Micro Macro Assets, LLC
11 patents
- Microsoft Technol…
Microsoft Technology, LLC.
11 patents
- Middle Atlantic P…
Middle Atlantic Products, Inc.
11 patents
- Miller Dowel
Miller Dowel Company
11 patents
- Mindspeed
Mindspeed Technologies, LLC.
11 patents
- Microvascular Tis… ◀
MicroVascular Tissues, Inc.
11 patents
What this shows Microvascular holds 11 patents at rank #24,811, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Microvascular's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
31 Top 62% higher than 38% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 1 | 9.1% |
| 2017 | 1 | 9.1% |
| 2018 | 2 | 18.2% |
| 2020 | 3 | 27.3% |
| 2022 | 2 | 18.2% |
| 2023 | 1 | 9.1% |
| 2025 | 1 | 9.1% |
Which technologies does Microvascular Tissues, Inc. patent most?
Top 5 of 5 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Standard
Velocity Accelerating
Frequently Asked Questions
How many patents does Microvascular Tissues, Inc. hold?
Microvascular Tissues, Inc. holds 11 US granted patents filed between 2015 and 2025, spanning 5 technology areas.
What is Microvascular Tissues, Inc.'s Innovation Score?
Microvascular Tissues, Inc. has an Innovation Score of 31.4 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Microvascular Tissues, Inc. focus on?
Microvascular Tissues, Inc.'s top technology area is C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA) with 11 patents. The company has filed patents in 5 CPC subclasses total.
Is Microvascular Tissues, Inc.'s patent filing rate increasing or decreasing?
Microvascular Tissues, Inc.'s recent filing velocity is +75% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Microvascular Tissues, Inc.'s patents?
Microvascular Tissues, Inc.'s patents average 13.7 claims each. This falls within the standard range, providing solid legal coverage.
How is the Microvascular Tissues, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Microvascular's 11 grants land it in the top 62% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Microvascular ranks #24,811 of 50,000. Top 50 holders
- Most of this portfolio concentrates in C12N - see who else leads that technology area. C12N leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.